EXECUTIVE SUMMARY

• Orthofix Raises Full-Year 2026 Guidance on Strong Limb Reconstruction and Spine Traction: Orthofix Medical raised full-year net sales guidance to $845M–$855M and adjusted EBITDA to $95M–$98M, propelled by double-digit growth in Limb Reconstruction and expanding surgeon adoption across its spinal fixation portfolio.
• Zimmer Biomet Accelerates Strategic Transition to Digital Surgery & Robotics: Market analysis highlights Zimmer Biomet's transition toward comprehensive digital operating room ecosystems, expanding ROSA® Shoulder and ROSA® Knee robotic platforms alongside smart sensor implants.
• OrthoCarolina and Advocate Health Unveil Major Physician-Led ASC Joint Venture: OrthoCarolina and Advocate Health announced a major partnership blueprint to develop physician-owned ambulatory surgery centers, advancing outpatient subspecialty surgical access across the Carolinas.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

Zimmer Biomet — Drives Ecosystem Expansion Beyond Implants with ROSA® Robotics and Sensor Technologies

• Summary: Zimmer Biomet's commercial strategy analysis details the company's accelerating shift from traditional hardware toward comprehensive digital surgery platforms. The expansion centers on the global rollout of the ROSA® Shoulder System—the first robotic platform supporting both glenoid and humeral bone preparation—alongside ROSA® Knee with OptimiZe™ and Persona IQ® smart knee implants, providing surgeons with objective intraoperative kinematics and longitudinal patient recovery data.
• Key Details:
• Device/System Name: ROSA® Shoulder System & Persona IQ® Smart Knee
• Status: Commercial Deployment / Digital Surgery Expansion
• Clinical Significance: Enhances resection accuracy and component positioning in joint replacement while generating objective post-operative kinematics to optimize recovery protocols.
• Original Source: Zimmer Biomet Digital Strategy Analysis — Orthopedics This Week

Trauma, Extremities & Limb Reconstruction

Orthofix Medical — Reports Strong 1H 2026 Results with Double-Digit Limb Reconstruction Growth

• Summary: Orthofix Medical released detailed operational results for the first half of 2026, driven by notable strength in its Limb Reconstruction division alongside solid gains in bone growth stimulation and spinal fixation. Building on commercial momentum in the US and Europe, the company raised full-year 2026 revenue guidance to $845M–$855M and adjusted EBITDA to $95M–$98M.
• Key Details:
• Device/System Name: Orthofix Limb Reconstruction & Bone Growth Therapies
• Status: 1H 2026 Financial Results / Raised Guidance
• Clinical Significance: Supports complex limb salvage, deformity correction, and biological bone union across challenging fracture and non-union cases.
• Original Source: Orthofix 1H 2026 Review — Orthopedics This Week

Bioretec Ltd. — Expands Commercial Reach of RemeOs™ Bioresorbable Magnesium Trauma Implants

• Summary: Bioretec Ltd. published its half-year 2026 financial and commercial report, highlighting expanding US and European distribution for its RemeOs™ bioresorbable magnesium alloy trauma screws. Designed to resorb naturally and be replaced by native bone over time, RemeOs offers mechanical strength comparable to traditional titanium implants while eliminating secondary implant removal operations.
• Key Details:
• Device/System Name: RemeOs™ Bioresorbable Magnesium Trauma Implants
• Status: Commercial Expansion / FDA Cleared & CE Marked
• Clinical Significance: Provides rigid fracture fixation with subsequent biological resorption, eliminating the morbidity, cost, and risks associated with hardware removal procedures.
• Original Source: Bioretec 2026 Half-Year Financial Report — Orthopedics This Week

Corporate, M&A & Healthcare Delivery

OrthoCarolina & Advocate Health — Establish Physician-Led ASC Joint Venture Model

• Summary: OrthoCarolina and Advocate Health (Atrium Health's Musculoskeletal Institute) unveiled a strategic alignment blueprint establishing a joint venture for physician-owned ambulatory surgery centers (ASCs). The agreement allows OrthoCarolina to remain independent and physician-led while leveraging shared health system infrastructure to accelerate the migration of high-acuity orthopaedic and spine procedures into cost-effective outpatient environments.
• Key Details:
• Device/System Name: OrthoCarolina / Advocate Health ASC Joint Venture
• Status: Strategic Partnership / Health System Alignment
• Clinical Significance: Expands access to high-volume outpatient surgical suites, optimizing procedural efficiency and patient satisfaction in outpatient total joint and spine procedures.
• Original Source: OrthoCarolina & Advocate Health Alignment — Orthopedics This Week

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)